Alnylam Pharmaceuticals, a Cambridge-based biotechnology firm, has received a (Dollar) 3.2m milestone payment from GlaxoSmithKline (GSK) as part of their ongoing collaboration to utilize Alnylam's RNA interference (RNAi) technology to develop GSK's cell-culture based influenza vaccine. While almost all other viral vaccines (e.g., mumps, measles, and polio) are currently produced via cell-culture, influenza vaccines have been resistant to cell-culture based manufacturing due to insufficient ...Thursday, 2 August 2012
Are the Concerns of Investor Hushed? Alnylam Achieves RNAi Milestone
Alnylam Pharmaceuticals, a Cambridge-based biotechnology firm, has received a (Dollar) 3.2m milestone payment from GlaxoSmithKline (GSK) as part of their ongoing collaboration to utilize Alnylam's RNA interference (RNAi) technology to develop GSK's cell-culture based influenza vaccine. While almost all other viral vaccines (e.g., mumps, measles, and polio) are currently produced via cell-culture, influenza vaccines have been resistant to cell-culture based manufacturing due to insufficient ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment